Latest news
AbbVie (ABBV) Stock May Be 45% Below Fair Value As Rinvoq Expands In Europe - simplywall.stsimplywall.st · Sat, 08 Aug 2026 07:46:03 GMTPrediction: AbbVie Will End The Year at This Price - 24/7 Wall St.24/7 Wall St. · Wed, 05 Aug 2026 14:00:26 GMTThe Bull Case For AbbVie (ABBV) Could Change Following EU Approval Of Rinvoq For Vitiligo - webull.comwebull.com · Tue, 04 Aug 2026 08:36:41 GMTWeekly Recap: Q2 revenue gain; EPS narrowed and Rinvoq EU nod for 12+ vitiligo - TradingViewTradingView · Mon, 03 Aug 2026 11:33:04 GMTAbbVie: Skyrizi And Rinvoq Generate $8.03 Billion As Humira Revenue Falls 36% - Pulse 2.0Pulse 2.0 · Mon, 03 Aug 2026 03:49:28 GMTAbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market - Fierce PharmaFierce Pharma · Fri, 31 Jul 2026 15:18:04 GMTAbbVie Has 2Q Beat Helped By Skyrizi and Rinvoq -- Market Talk - MoomooMoomoo · Fri, 31 Jul 2026 13:34:00 GMTAbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo - PMLiVEPMLiVE · Fri, 31 Jul 2026 11:41:32 GMT